A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's Lymphoma

Pediatric Non-Hodgkin Lymphoma Clinical Trial

Official title:

A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04469543
• Other study ID #: SCCCG-NHL2017
• Status: Completed
• Start date: January 20, 2014
• Est. completion date: May 20, 2020

Study information

• Verified date: July 2020
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary purpose of this retrospective study was to investigate the influence of methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphism on the survival of pediatric patients with Non-Hodgkin lymphoma (NHL) treated with modified NHL-BFM95 protocol in south China.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 374
• Est. completion date: May 20, 2020
• Est. primary completion date: February 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

1. aged = 18 years;

2. newly diagnosed as the four main categories of NHL(Burkitt's lymphoma, lymphoblastic lymphoma, anaplastic large cell lymphoma, and diffuse large B-cell lymphoma) between 2014 and 2020;

3. treated according to the modified BFM95 protocol.

Exclusion Criteria:

1. aged > 18 years;

2. not newly diagnosed as the four main categories of NHL between 2014 and 2020;

3. treated according to chemotherapeutic regimens except for the modified BFM95 protocol.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Pediatric Non-Hodgkin Lymphoma

Locations

Country	Name	City	State
China	Sun Yat-Sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Death	Overall survival time was calculated from the time of initial diagnosis to death	About six years
Primary	Events including progression, relapse, and secondary cancer	Event-free survival (EFS) time was calculated from the time of initial diagnosis to first event.	About six years